DrugBiological
Factor VIII clinical trials
- studies test it
- 10
- open now
- 0
- in phase 3
- 5
- first study started
- 1998
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 1
- Phase 3
- 5
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
CSL Behring (5) · Children's Hospital Los Angeles (1) · Novo Nordisk A/S (1) · Chulalongkorn University (1) · Hospices Civils de Lyon (1) · Beijing Children's Hospital (1)
Often tested with
Tested in the same studies.
Von Willebrand Factor (5) · Antihemophilic factor, human recombinant (3) · F8 protein, human (3) · Recombinant FVIIa (1) · Prednisone (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses Factor VIII is read from its arms, and is right about nine times in ten.
Testing it · 10
- Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedPhase 4Novo Nordisk A/SNCT01561391Written as factor VIII
- Preventing Inhibitor Recurrence IndefinitelyActive, not recruitingPhase 4Children's Hospital Los AngelesNCT04621916Written as FVIII
- Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaStatus unknownPhase 4Beijing Children's HospitalNCT03598725Written as Coagulation Factor VIII
- Study of Biostate® in Children With Von Willebrand DiseaseCompletedPhase 3CSL BehringNCT01213446Written as Biostate
- Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand DiseaseCompletedPhase 2/3CSL BehringNCT00941616Written as Biostate®
- Extension Study of Biostate in Subjects With Von Willebrand DiseaseCompletedPhase 3CSL BehringNCT01224808Written as Biostate
- Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody DevelopmentTerminatedPhase 3CSL BehringNCT01445197Written as Biostate
- Study of Biostate® in Children With Hemophilia ACompletedPhase 3CSL BehringNCT01229007Written as Biostate
- Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric PatientsCompletedPhase 4Chulalongkorn UniversityNCT02727647Written as FVIII
- Individually Tailored Prophylaxis in Patients With Severe Hemophilia ATerminatedNot applicableHospices Civils de LyonNCT00995046Written as FVIII
Given in every arm · 3 — Factor VIII is usual care beside what is tested
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02847637Written as Factor VIII (FVIII)
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia ACompletedPhase 3Bioverativ Therapeutics Inc.NCT01181128Written as Factor VIII (rFVIIIFc)
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ACompletedPhase 3Bioverativ Therapeutics Inc.NCT01458106Written as FVIII (PK subgroup only)
As the comparator · 3 — what is tested is compared with Factor VIII
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06998524Written as Factor VIII (FVIII) Concentrates
- Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A PatientsNot yet recruitingPhase 2/3Dhaka Medical CollegeNCT06938659Written as Factor VIII (FVIII)
- Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia ACompletedPhase 2CSL BehringNCT00879541Written as Biostate® [RP]
Codes
What other systems call Factor VIII · ClinicalTrials.gg INT007470
- MeSH (NLM) D005169Factor VIIIOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005169 | Factor VIII | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.